soul trial oral semaglutide cardiovascular outcomes 2024 results nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine soul trial oral semaglutide cardiovascular

These findings showcase the need for careful consideration and monitoring of patients prescribed semaglutide, given the elevated risks of serious eye conditions associated with its use

DecramerMRutten-van MlkenMDekhuijzenPTroostersTvan HerwaardenCPellegrinoRet al

It helps reduce the appearance of fine lines, wrinkles, and age spots

However, no consistent significant increase in hemolysis was observed both in nave and P

The SURMOUNT-5 Trial: Head-to-Head Results SURMOUNT-5 was a 72-week, randomised, open-label Phase 3b trial that enrolled 751 adults with obesity (or overweight with at least one weight-related condition) and without diabetes

Nyathi Y, Wilkinson BM, Pool MR (2013) Co-translational targeting and translocation of proteins to the endoplasmic reticulum